Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (SLDB) has announced the granting of 11,950 restricted stock units (RSUs) to a newly hired employee. The RSUs are structured with a four-year vesting schedule, with 25% of the units vesting annually on each grant date anniversary. The equity award, issued under the Company's 2024 Inducement Stock Incentive Plan, serves as an employment inducement and complies with Nasdaq Listing Rule 5635(c)(4). The vesting is contingent upon the employee's continued service with the company through each vesting date.

Solid Biosciences (SLDB) has announced the pricing of an underwritten offering, consisting of 35,739,810 shares of common stock at $4.03 per share and pre-funded warrants to purchase 13,888,340 shares at $4.029 per warrant. The offering is expected to generate approximately $200.0 million in gross proceeds before deductions.

The pre-funded warrants will have an exercise price of $0.001 per share and will be immediately exercisable. The offering, expected to close around February 19, 2025, includes participation from notable investors such as Adage Capital Partners, Bain Capital Life Sciences, Invus, Perceptive Advisors, and RA Capital Management, among others.

Jefferies, Leerink Partners, and William Blair are serving as joint book-running managers, with H.C. Wainwright & Co. acting as lead manager for the offering.

Solid Biosciences (NASDAQ: SLDB) reported positive initial data from its Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy. The 90-day biopsy data from the first three participants showed an average microdystrophin expression of 110% and significant improvements in muscle health biomarkers.

The therapy has been well-tolerated in six participants dosed as of February 11, 2025, with no serious adverse events reported. Common adverse events included nausea, vomiting, fever, and transient declines in platelets. Early signals of potential cardiac benefits were observed.

The company continues enrollment, with the seventh participant dosed on February 17, 2025, and expects to dose approximately 20 total participants by Q4 2025. Solid Biosciences plans to request an FDA meeting in mid-2025 to discuss potential accelerated approval pathway for SGT-003.

Solid Biosciences (SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 31,101 restricted stock units (RSUs) to two new employees. The RSUs are structured to vest in four equal annual installments, with complete vesting occurring on the fourth anniversary of the grant date. The grants were issued under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.

Solid Biosciences (SLDB) has received Fast Track designation from the FDA for SGT-212, its dual-route gene therapy candidate for Friedreich's ataxia (FA). SGT-212 is designed to deliver the full-length frataxin gene through both intradentate nucleus and intravenous infusions to address neurologic, cardiac, and systemic manifestations of FA.

The Fast Track status, granted to products treating serious conditions with unmet medical needs, will facilitate more frequent FDA interactions and potential priority review eligibility. The company received FDA IND clearance on January 7th, 2025, and plans to initiate a Phase 1b trial in the second half of 2025. This first-in-human, open-label, multicenter study will evaluate safety and tolerability in both ambulatory and non-ambulatory FA patients, with a five-year follow-up period.

Solid Biosciences (NASDAQ: SLDB) provided updates on its neuromuscular and cardiac development pipeline. The company has dosed four patients in the INSPIRE DUCHENNE trial for SGT-003, with initial three-patient data expected in Q1 2025. The FDA cleared an IND for SGT-212, a dual-route administration gene therapy for Friedreich's ataxia, with first-in-human trials planned for 2H 2025.

The company plans to submit an IND for SGT-501 to treat CPVT in 1H 2025. Additionally, Solid is advancing SGT-601 for TNNT2 Thin Filament Cardiomyopathy with IND submission planned for 2H 2026. The company has also collaborated with Mayo Clinic for developing therapies for cardiac conditions.

Solid enters 2025 with approximately $148.9 million in cash and investments, expected to fund key priorities into 2026.

Solid Biosciences (SLDB), a precision genetic medicines developer focusing on neuromuscular and cardiac diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Bo Cumbo, President and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET).

The presentation will be accessible through a live webcast on the Company's website's Investors section under the Events page. A replay of the webcast will remain available for 30 days following the event. Institutional investors seeking meetings with management during the conference are advised to contact their J.P. Morgan representatives.

Solid Biosciences (NASDAQ: SLDB) has received FDA IND clearance for SGT-212, a pioneering dual-route gene therapy designed to treat Friedreich's ataxia (FA). This therapy is unique as it's the only candidate delivering full-length frataxin protein through both systemic intravenous infusion and direct intradentate nuclei infusion into the cerebellum.

The therapy aims to address both neurologic and cardiac manifestations of FA, targeting the insufficient levels of frataxin protein that cause this degenerative disease. Preclinical studies have shown safe transduction and frataxin expression in target tissues, demonstrating significant restoration of neurologic function and reversal of cardiac implications in mice.

The company plans to initiate a Phase 1b clinical trial in the second half of 2025. This first-in-human, open-label, dose-finding study will enroll both non-ambulatory and ambulatory adult FA patients across up to three cohorts, with participants being followed for five years after receiving SGT-212.

Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced on January 6, 2025, the grant of 11,847 restricted stock units (RSUs) to a newly hired employee.

The RSUs will vest in four equal installments on each one-year anniversary of the grant date, provided the employee continues to serve with the company through each vesting date. This grant was made under the company's 2024 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4).